GlassScriptPhysician profile
Francois Picot
NPI 1215914080
$724.37
in general payments reported to CMS, 2019-2025
11 companies · $55.88 in 2025
The $55.88 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $189 · 2023: $479 · 2025: $55.88.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $535.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $534.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $277.94 | 2022-2023 | |
| Pfizer INC. | $120.38 | 2023-2025 | |
| Lilly USA, LLC | $86.03 | 2022-2023 | Amyvid, Emgality, Reyvow |
| Biohaven Pharmaceutical Holding Company LTD. | $50.92 | 2022 | |
| Celgene Corporation | $42.20 | 2022-2023 | Zeposia |
| Collegium Pharmaceutical, INC. | $30.98 | 2022 | |
| Novartis Pharmaceuticals Corporation | $26.36 | 2022-2023 | |
| Impel Pharmaceuticals INC. | $24.67 | 2023 | Trudhesa |
| Upsher-Smith Laboratories LLC | $22.49 | 2023 | |
| Argenx US, INC. | $21.90 | 2023 | Vyvgart |
| Biogen, INC. | $20.50 | 2023 | Vumerity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Francois Picot listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.